{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T07:29:11Z","timestamp":1765438151971},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,8,9]],"date-time":"2009-08-09T00:00:00Z","timestamp":1249776000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1007\/s00280-009-1081-y","type":"journal-article","created":{"date-parts":[[2009,8,8]],"date-time":"2009-08-08T15:13:27Z","timestamp":1249744407000},"page":"755-763","source":"Crossref","is-referenced-by-count":21,"title":["Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes"],"prefix":"10.1007","volume":"65","author":[{"given":"Alison","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elzbieta","family":"Nowara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Welt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadeusz","family":"Pienkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Rolski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"My-Linh","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Perraud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Trillet-Lenoir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,8,9]]},"reference":[{"key":"1081_CR1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/ije\/dyh414","volume":"34","author":"MD Althuis","year":"2005","unstructured":"Althuis MD, Dozier JD, Anderson WF et al (2005) Global trends in breast cancer incidence and mortality 1973\u20131997. Int J Epidemiol 34:405\u2013412","journal-title":"Int J Epidemiol"},{"key":"1081_CR2","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2005.05.2308","volume":"24","author":"F Kamangar","year":"2006","unstructured":"Kamangar F, Dores GM, Anderson WF et al (2006) Patterns of cancer incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137\u20132150","journal-title":"J Clin Oncol"},{"key":"1081_CR3","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1200\/JCO.2003.11.071","volume":"21","author":"V Valero","year":"2003","unstructured":"Valero V, Hortobagyi GN (2003) Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? J Clin Oncol 21:959\u2013962","journal-title":"J Clin Oncol"},{"key":"1081_CR4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.1706","volume":"205","author":"DB Longley","year":"2005","unstructured":"Longley DB, Johnston PG (2005) Molecular mechanism of drug resistance. J Pathol 205:275\u2013292","journal-title":"J Pathol"},{"key":"1081_CR5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1634\/theoncologist.9-6-617","volume":"9","author":"C Bernard-Marty","year":"2004","unstructured":"Bernard-Marty C, Cardoso F, Piccart MJ (2004) Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 9:617\u2013632","journal-title":"Oncologist"},{"key":"1081_CR6","first-page":"5","volume":"16","author":"S Binet","year":"1989","unstructured":"Binet S, Fellous A, Lataste H et al (1989) In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence. Semin Oncol 16:5\u20138","journal-title":"Semin Oncol"},{"issue":"1","key":"1081_CR7","first-page":"35","volume":"21","author":"G Freyer","year":"2003","unstructured":"Freyer G, Delozier T, Lichinister M et al (2003) Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 21(1):35\u201340","journal-title":"J Clin Oncol"},{"issue":"3","key":"1081_CR8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1359-6349(04)90882-8","volume":"2","author":"V Trillet-Lenoir","year":"2004","unstructured":"Trillet-Lenoir V, Sommer H, Delozier T et al (2004) Oral vinorelbine in metastatic breast cancer: long-term results of 2 phase II studies. Eur J Cancer Suppl 2(3):137 (abstract 279)","journal-title":"Eur J Cancer Suppl"},{"issue":"5","key":"1081_CR9","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1016\/S1359-6349(03)90826-3","volume":"1","author":"C Gridelli","year":"2003","unstructured":"Gridelli C, Parlier Y, Brandely M et al (2003) Oral chemotherapy and upper gastro-intestinal tolerance improvement of nausea and vomiting in non-small cell lung cancer patients treated with oral navelbine and standard antiemetic prophylaxis. Eur J Cancer Suppl 1(5):S240\u2013S241 (abstract 801)","journal-title":"Eur J Cancer Suppl"},{"key":"1081_CR10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","volume":"15","author":"G Liu","year":"1997","unstructured":"Liu G, Franssen E, Fitch MI et al (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110\u2013115","journal-title":"J Clin Oncol"},{"key":"1081_CR11","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1023\/A:1013180903805","volume":"12","author":"M Marty","year":"2001","unstructured":"Marty M, Fumoleau P, Adenis A et al (2001) Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12:1643\u20131649","journal-title":"Ann Oncol"},{"key":"1081_CR12","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/CAD.0b013e3282f945aa","volume":"19","author":"MW Saif","year":"2008","unstructured":"Saif MW, Katirzoglou NA, Syrigos KN (2008) Capecitabine: an overview of the side effects and their management. Anticancer Drugs 19:447\u2013464","journal-title":"Anticancer Drugs"},{"key":"1081_CR13","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ejca.2003.11.007","volume":"40","author":"P Fumoleau","year":"2004","unstructured":"Fumoleau P, Largillier R, Clippe C et al (2004) Multicenter phase II study evaluating capecitabine monotherapy in patients with anthracyclines and taxane pretreated metastatic breast cancer. Eur J Cancer 40:536\u2013542","journal-title":"Eur J Cancer"},{"issue":"1","key":"1081_CR14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clinthera.2005.01.005","volume":"27","author":"CM Walko","year":"2005","unstructured":"Walko CM, Lindley C (2005) Capecitabine: a review. Clin Ther 27(1):23\u201344","journal-title":"Clin Ther"},{"key":"1081_CR15","unstructured":"Sawada N, Fujimoto-Ouchi F, Ishikawa T et al (2002) Antitumor activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models. Proc Am Assoc Cancer Res 43:1088 (abstract 5388)"},{"issue":"Suppl 7","key":"1081_CR16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/annonc\/mdl942","volume":"17","author":"V Lorusso","year":"2006","unstructured":"Lorusso V, Spada M, Giampaglia M et al (2006) Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (MBC). A phase II study of the GOIM (Gruppo Oncologico d\u2019ell\u2019Italia Meridionale). Ann Oncol 17(Suppl 7):15\u201317","journal-title":"Ann Oncol"},{"key":"1081_CR17","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3346\/jkms.2004.19.4.547","volume":"19","author":"JH Ahn","year":"2004","unstructured":"Ahn JH, Kim SB, Kim TW, Ahn SH et al (2004) Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines and taxane. J Korean Med Sci 19:547\u2013553","journal-title":"J Korean Med Sci"},{"key":"1081_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1743-7563.2006.00086.x","volume":"3","author":"AJ Davis","year":"2007","unstructured":"Davis AJ, Brew S, Gebski VJ et al (2007) Multicenter phase II study of combination chemotherapy with capecitabine and intravenous vinorelbine in patients with pretreated metastatic breast cancer. Asia Pac J Clin Oncol 3:1\u20137","journal-title":"Asia Pac J Clin Oncol"},{"key":"1081_CR19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/annonc\/mdi024","volume":"16","author":"A Welt","year":"2005","unstructured":"Welt A, Von Minckwitz G, Oberhoff C et al (2005) Phase I\/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol 16:64\u201369","journal-title":"Ann Oncol"},{"key":"1081_CR20","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/annonc\/mdh467","volume":"15","author":"D Hess","year":"2004","unstructured":"Hess D, Thurlimann B, Pagani O et al (2004) Capecitabine and vinorelbine in elderly patients (\u226565\u00a0years) with metastatic breast cancer: a phase I trial (SAKK 25\/99). Ann Oncol 15:1760\u20131765","journal-title":"Ann Oncol"},{"key":"1081_CR21","unstructured":"Stuart N, Bishop L, Johnson SRD et al (2003) Vinorelbine and capecitabine for advanced breast cancer. A phase II study showing good activity and potential for further development. Proc Am Soc Clin Oncol (Abstr 183)"},{"key":"1081_CR22","first-page":"2451","volume":"26","author":"M Ghosn","year":"2006","unstructured":"Ghosn M, Kattan J, Farhat F et al (2006) Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients. Anticancer Res 26:2451\u20132456","journal-title":"Anticancer Res"},{"key":"1081_CR23","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/annonc\/mdj058","volume":"17","author":"F Nol\u00e8","year":"2006","unstructured":"Nol\u00e8 F, Catania G, Senna G et al (2006) Dose finding and pharmacokinetic study of an all-oral combination of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol 17:322\u2013329","journal-title":"Ann Oncol"},{"issue":"4","key":"1081_CR24","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00280-008-0915-3","volume":"64","author":"F Nol\u00e8","year":"2009","unstructured":"Nol\u00e8 F, Crivellari D, Mattioli R et al (2009) Phase II study of an all oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 64(4):673\u2013680","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"1081_CR25","first-page":"667","volume":"29","author":"J Finek","year":"2009","unstructured":"Finek J, Holubec L Jr, Svoboda T et al (2009) A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer. Anticancer Res 29(2):667\u2013670","journal-title":"Anticancer Res"},{"key":"1081_CR26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00944177","volume":"10","author":"S Green","year":"1992","unstructured":"Green S, Weiss G (1992) Southwest Oncology Group standard response criteria, endpoint definition and toxicity criteria. Invest New Drugs 10:239\u2013253","journal-title":"Invest New Drugs"},{"key":"1081_CR27","doi-asserted-by":"crossref","unstructured":"Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. New Eng J Med 328:1323\u20131332","DOI":"10.1056\/NEJM199305063281808"},{"key":"1081_CR28","doi-asserted-by":"crossref","unstructured":"Carrick S, Parker S, Thornton CE et al (2009) Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 18(2):CD003372","DOI":"10.1002\/14651858.CD003372.pub3"},{"issue":"15","key":"1081_CR29","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.ejca.2008.07.019","volume":"44","author":"N Wilcken","year":"2008","unstructured":"Wilcken N, Dear R (2008) Chemotherapy in metastatic breast cancer: a summary of all randomized trials reported 2000\u20132007. Eur J Cancer 44(15):2218\u20132225","journal-title":"Eur J Cancer"},{"issue":"3","key":"1081_CR30","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3816\/CBC.2008.n.026","volume":"8","author":"C Bunnell","year":"2008","unstructured":"Bunnell C, Vahdat L, Schwartzberg L et al (2008) PhaseI\/II study of ixabepilone plus capecitabine in anthracycline-pretreated\/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer 8(3):234\u2013241","journal-title":"Clin Breast Cancer"},{"key":"1081_CR31","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1200\/JCO.2007.12.6557","volume":"25","author":"ES Thomas","year":"2007","unstructured":"Thomas ES, Gomez HL, Li RK et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210\u20135217","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"1081_CR32","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1053\/j.seminoncol.2008.02.008","volume":"35","author":"W Dean-Colomb","year":"2008","unstructured":"Dean-Colomb W, Esteva FJ (2008) Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer. Semin Oncol 35(Suppl 2):S31\u2013S38","journal-title":"Semin Oncol"},{"key":"1081_CR33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00001813-200603000-00013","volume":"17","author":"T Petit","year":"2006","unstructured":"Petit T, Benider A, Yocine A et al (2006) Phase II study of an oxaliplatin\/vinorelbine combination in patients with anthracycline-and taxane-pre-treatedmetastatic breast cancer. Anticancer Drugs 17:337\u2013343","journal-title":"Anticancer Drugs"},{"key":"1081_CR34","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s12094-007-0085-5","volume":"9","author":"R Sanchez-Escribano Morcuende","year":"2007","unstructured":"Sanchez-Escribano Morcuende R, Ales-Martinez JE, Aramburo Gonzalez PM (2007) Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapse breast cancer after taxane- anthracycline-containing regimens. Clin Transl Oncol 9:459\u2013464","journal-title":"Clin Transl Oncol"},{"key":"1081_CR35","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/(SICI)1097-0142(19980101)82:1<134::AID-CNCR16>3.0.CO;2-3","volume":"82","author":"I Ray-Coquard","year":"1998","unstructured":"Ray-Coquard I, Biron P, Bachelot T et al (1998) Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and\/or paclitaxel-containing regimens. Cancer 82:134\u2013140","journal-title":"Cancer"},{"key":"1081_CR36","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.bjc.6605156","volume":"101","author":"N Tubiana-Mathieu","year":"2009","unstructured":"Tubiana-Mathieu N, Bougnoux P, Becquart D et al (2009) All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II trial. British J Cancer 101:232\u2013237","journal-title":"British J Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1081-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-009-1081-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1081-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T13:37:23Z","timestamp":1633786643000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-009-1081-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,9]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["1081"],"URL":"https:\/\/doi.org\/10.1007\/s00280-009-1081-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,9]]}}}